<DOC>
	<DOCNO>NCT01642017</DOCNO>
	<brief_summary>This open-label , multicenter , non-randomized , phase 1 dose escalation clinical trial determine MTD ( Maximal Tolerated Dose ) Pazopanib population frail elderly patient , select accord International Society Geriatric Oncology ( SIOG ) classification ( Group 2 ) . It expect total number 30 patient maximum enrol study 30 month : 18 month accrual - 12 month follow . Eligible patient enrol standard 3+3 design start dose Pazopanib administer orally 400 mg per day , 28-day cycle . Then , dose level explore . Toxicity schedule assess first cycle . Patients receive study medication disease progression . After treatment discontinuation , patient follow one year .</brief_summary>
	<brief_title>Phase I Clinical Pharmacokinetic Study Pazopanib Population Frail Elderly Patients According SIOG Criteria</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Subjects must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment follow . 2 . Age ≥ 75 year old 3 . Patient metastatic cancer among renal cell carcinoma , non small cell lung cancer , pancreatic neuroendocrine cancer , sarcoma , ovarian cancer , thyroid cancer , bladder cancer breast cancer , receive treatment curative intent . 4. WHO PS ≤ 2 , 5 . Life expectancy ≥ 3 month , 6 . Group 2 ( vulnerable ) accord SIOG classification , 7 . Adequate organ system function define provide Table 1 . Patient history prior malignancy exception cervical intraepithelial neoplasia ; basal cell carcinoma skin ; adequately treat localized prostate carcinoma PSA &lt; 1.0 ; undergone potentially curative therapy evidence disease five year , deem low risk recurrence his/her treat physician , 2 . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . 3 . Criteria group 3 accord SIOG classification , 4 . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include , limited : •Active peptic ulcer disease •Known intraluminal metastatic lesion/s risk bleed •Inflammatory bowel disease ( e.g . ulcerative colitis , crohn 's disease ) , gastrointestinal condition increase risk perforation •History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . 5 . Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : •Malabsorption syndrome •Major resection stomach small bowel . 6 . Presence uncontrolled infection . 7 . Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula 8 . Anticoagulants treatment ( preventive curative ) 9 . History one follow cardiovascular condition within past 6 month : • Cardiac angioplasty stenting • Myocardial infarction • Unstable angina • Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) 10 . Poorly control hypertension 11 . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . 12 . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer 13 . Evidence active bleeding bleed diathesis . 14 Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel 15 . Hemoptysis excess 2.5 mL ( one half teaspoon ) within 8 week first dose study drug . 16 . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . 17 . Unable unwilling discontinue use prohibit medication list Appendix 7 least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study 18 . Treatment follow anticancer therapy : radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib OR chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib 19 . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia . 20 . Patient affiliate social system France . 21 . Patient deprive liberty guardianship</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Phase I , Pazopanib , Frail elderly patient , Pharmacokinetics</keyword>
</DOC>